Lipella Pharmaceuticals, Inc. (LIPO) - Total Stockholders' Equity

This price chart on the GURU.Markets platform illustrates the price action of Lipella Pharmaceuticals (LIPO), which has developed a targeted treatment system for critical urological bleeding via liposomal delivery. Revenue is based on the sale of tissue regeneration agents for inflammation, where the indicator stands at 0.01. However, growth potential is limited by a linear increase in expenses during the development of bladder cancer drugs at the trial stage.

Lipella Pharmaceuticals focuses on building a highly specialized talent pool for the development of urological drugs, which requires stable funding for fundamental research. By analyzing the company's book capitalization valuation, an investor can see the net equity value minus all liabilities, allowing them to filter out market noise and determine the actual intrinsic value of the issuer's assets.